Discontinued — last reported Q4 '25
Nucor Acquisitions decreased by 100.0% to $0.00 in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $109.93M to $0.00. Over 3 years (FY 2021 to FY 2024), Acquisitions shows a downward trend with a -19.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $1.35B | $79.82M | $347.18M | $3.12B | $83.90M | $3.43M | $17.71M | $17.71M | $17.71M | $17.71M | -$991.00K | $109.93M | $563.25M | $85.81M | $1.00M | $0.00 |
| QoQ Change | — | — | -94.1% | +335.0% | +798.3% | -97.3% | -95.9% | +416.7% | +0.0% | +0.0% | +0.0% | -105.6% | >999% | +412.4% | -84.8% | -98.8% | -100.0% |
| YoY Change | — | — | — | — | — | -93.8% | -95.7% | -94.9% | -99.4% | -78.9% | +416.7% | -105.6% | +520.9% | >999% | +384.6% | +200.9% | -100.0% |